Gastrointestinal stromal tumor Market Size 2023 Market Share, Top Companies report covers (Novartis,Bayer Aktiengesellschaft,Sun Pharmaceutical,Pfizer,NATCO Pharma), and Regional Analysis by Key Players,Segmentation and Forecast
January 24, 2023 07:03 ET
|
Proficient Market Insights
PUNE, Jan. 24, 2023 (GLOBE NEWSWIRE) -- "Gastrointestinal stromal tumor Market" research report focus on overall information that can help to take decisions on current market situation....
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
January 09, 2023 10:33 ET
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
October 12, 2022 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
September 07, 2022 09:00 ET
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight...
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
July 27, 2022 08:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
Bispecific Molecules in Oncology Analytical Tool 2022: Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
July 22, 2022 04:13 ET
|
Research and Markets
Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "Bispecific Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Bispecific Molecules in Oncology:...
Global Oncology Based In-Vivo CRO Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
July 19, 2022 05:59 ET
|
Research and Markets
Dublin, July 19, 2022 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Global NGS Oncology Market Report 2022-2032: Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques Driving Growth
July 13, 2022 07:43 ET
|
Research and Markets
Dublin, July 13, 2022 (GLOBE NEWSWIRE) -- The "NGS Oncology Market - A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region - Analysis...